1
|
Denis MG, Lafourcade MP, Le Garff G, Dayen C, Falchero L, Thomas P, Locher C, Oliviero G, Licour M, Reck M, Normanno N, Molinier O. Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. J Thorac Dis 2019; 11:1370-1378. [PMID: 31179079 DOI: 10.21037/jtd.2019.03.95] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Background The non-interventional ASSESS study (NCT01785888) evaluated the utility of circulating free tumor-derived DNA (ctDNA) from plasma for epidermal growth factor receptor (EGFR) mutation testing in patients with advanced non-small-cell lung cancer (NSCLC), in a real-world setting across 56 centers in Europe and Japan. The high mutation status concordance between 1162 matched tissue/cytology and plasma samples (89%, sensitivity =46%, specificity =97%) suggested that ctDNA is a feasible sample for EGFR mutation analysis. We report data for the French subset of patients (pre-planned analysis). Methods Eligible patients (stage IIIA/B/IV locally advanced/metastatic treatment-naive advanced NSCLC) provided diagnostic tissue/cytology and plasma samples. DNA extracted from tissue/cytology samples was subjected to EGFR mutation testing as per local practice; a designated laboratory performed ctDNA extraction/mutation testing of plasma samples. The primary outcome was EGFR mutation status concordance between matched tumor and plasma samples. Results Of the 1,311 patients enrolled in the ASSESS trial, 145 were recruited from 9 centers in France. Tumor samples from 130 patients were collected and 126 were evaluable for EGFR mutation analysis. Activating EGFR mutations were identified in 13 of the 126 patient tumor samples (EGFR mutation frequency 10.3%). For plasma testing, 10 of the 145 samples tested were positive for EGFR mutations (EGFR mutation frequency 6.9%). EGFR mutation rate was significantly higher in never- versus ever-smokers (stepwise logistic regression: tumor, P<0.0001; plasma, P=0.0008). Mutation status concordance between 126 matched patient samples was 96.0% [121/126; 95% confidence intervals (CI), 91.0-98.7]. Of the 113 EGFR mutation-negative patient tissue samples, one tested plasma-positive; reanalysis of plasma via two different techniques confirmed the presence of a L858R mutation, indicating a tissue false-negative result. Based on these data, sensitivity of plasma testing was 64.3% (9/14; 95% CI, 35.1-87.2%) and its specificity was 100.0% (112/112; 95% CI, 96.8-100.0%). Conclusions Data confirm ctDNA as an alternative sample for EGFR mutation analysis in patients with advanced NSCLC.
Collapse
Affiliation(s)
- Marc G Denis
- Department of Biochemistry and INSERM U1232, Nantes University Hospital, 9 quai Moncousu, F-44093 Nantes Cedex, France
| | | | - Gwenaëlle Le Garff
- Centre Hospitalier Hôpital Yves Le Foll, 10 r Marcel Proust, 22027 St Brieuc, France
| | - Charles Dayen
- Centre Hospitalier De Saint Quentin, 1 av Michel de l'Hôpital, Saint-Quentin, France
| | - Lionel Falchero
- Centre Hospitalier Villefranche-Sur-Saône, 69655 Villefranche-sur-Saône Cedex, France
| | - Pascal Thomas
- Centre Hospitalier Intercommunal des Alpes du Sud, 1 pl Auguste Muret, 05007 Gap, France
| | - Chrystèle Locher
- Centre Hospitalier de Meaux, 6-8 r Saint Fiacre, 77104 Meaux, France
| | - Gérard Oliviero
- Centre Hospitalier de Longjumeau, 159 r Prés François Mitterrand, 91160 Longjumeau, France
| | - Muriel Licour
- AstraZeneca, Tour Carpe Diem, 31 place des Corolles, 92400 Courbevoie, France
| | - Martin Reck
- Department of Thoracic Oncology, LungenClinic Grosshansdorf GmbH, Airway Research Centre North, Member of the German Centre for Lung Research (DZL), Grosshansdorf, Germany
| | - Nicola Normanno
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione Pascale", IRCCS, Naples, Italy
| | - Olivier Molinier
- Centre Hospitalier Du Mans, 194 av Rubillard, 72037 Le Mans, France
| |
Collapse
|
2
|
Dayen C, Coëtmeur D, Lecerf C, Diximier A, Lemaire B, Martin M, Lafourcade MP, Fraboulet G, Leveiller G, Lecuyer E, Mathieu JP, Nocent-Ejnaini C, Dumont P, Peureux M, Dehette S, Locher C, Le Treut J, Debieuvre D, Martin F, Grivaux M. Study KBP-2010-CPHG: Characteristics and management of 968 new cases of small-cell lung cancer (SCLC). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e19078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19078 Background: In recent years, many major advances have been made in non-small-cell lung cancer (NSCLC), and in particular in adenocarcinoma, but not in SCLC. In 2010, the French College of General Hospital Respiratory Physicians (CPHG) performed a prospective multicentre epidemiological study (KBP-2010-CPHG) to describe the baseline characteristics and management of all new cases of primary lung cancer and to evaluate survival. The present abstract reports results in SCLC patients. Methods: 7,051 patients ≥18 years presenting with a new case of primary lung cancer, histologically or cytologically diagnosed between 1 January and 31 December 2010 and managed in the respiratory department of one of the 104 general hospitals participating in the study, were included. A standardised form was completed for each patient. A steering committee checked data collection exhaustiveness. SCLC data were analysed separately. Results: There were 968 SCLC patients: mean age, 65.6 years (+/-10.6); 23.2% female; 4.4% non-smokers (11 % in women), 35.8% ex-smokers, 59.8% current smokers; 63.4% with performance status 0 or 1; 59.9% having lost weight within the previous 3 months (19.8% of whom had lost >10 kg). Main tumour characteristics at diagnosis were: 71.2% stage IV, 24.7% stage IIIA or IIIB, 4.1% of stage <III. 15.2% of patients received chemo-radiotherapy and 73.4% chemotherapy (86.2% platinum-based). Carboplatin was more commonly used in patients >70 (59.1%) than <70 years of age (40.9 %). One-year mortality was 64.2%. Compared with NSCLC patients, patients with SCLC more frequently were active smokers (59.8% vs.47.6%), lost weight (59.9% vs. 52.4%), and presented with stage IV tumour at diagnosis (71.2% vs. 58.3%); first line therapy was more frequently platinum-based chemotherapy (86.2% vs. 61.2%) and less frequently curative surgery (1.6% vs. 19%), and mortality was higher (64.2% vs. 55.2%). Conclusions: In 2010, prognosis remains poor in SCLC. Compared with NSCLC, it was more frequently associated with active smoking and stage IV disease, and showed a lower rate of surgery.
Collapse
Affiliation(s)
- Charles Dayen
- Centre Hospitalier De Saint Quentin, Saint Quentin, France
| | - Daniel Coëtmeur
- Centre Hospitalier St Brieuc-Hôpital Yves Le Foll, Saint-Brieuc, France
| | - Celine Lecerf
- Centre Hospitalier De Saint Quentin, Saint Quentin, France
| | - Adrien Diximier
- Centre Hôspitalier D'orléans - Hôpital De La Source, Orléans, France
| | - Bertrand Lemaire
- Centre Hôspitalier D'orléans - Hôpital De La Source, Orléans, France
| | - Michel Martin
- Centre Hospitalier D’Angoulême, Saint-Michel, France
| | | | | | | | | | | | | | - Patrick Dumont
- Centre Hospitalier De Chauny - Service de Pneumologie, Chauny, France
| | | | | | | | - Jacques Le Treut
- Centre Hospitalier Aix en Provence, Aix En Provence Cedex 1, France
| | | | | | | |
Collapse
|
3
|
Dron P, Lafourcade MP, Leprince F, Nonotte-Varly C, Van Der Brempt X, Banoun L, Sullerot I, This-Vaissette C, Parisot L, Moneret-Vautrin DA. Allergies associated with body piercing and tattoos: a report of the Allergy Vigilance Network. Eur Ann Allergy Clin Immunol 2007; 39:189-92. [PMID: 17713170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Body piercing and tattooing are increasingly common. As well as the risk of infection and scarring, allergic reactions are also reported. This is the first multi-centre study to assess the frequency of consultations for allergy. Of the 138 allergologists who answered our two questionnaires, 7.9% reported allergic reactions associated with body piercing and 18.9% identified allergies associated with temporary henna-based tattoos. Contact eczema, rhinitis and urticaria were related to nickel allergy. Contact eczema, generalized eczema, pruritus and edema were caused by tattoos. In 20 out of 28 cases, sensitization to para-phenylenediamine (PPD) was observed. The authors review the literature, underscoring the risk of serious allergy to PPD, the need for long-term monitoring of the risk of skin lymphocytoma, the difficulties met during treatment and the necessity of regulating tattooing and body piercing practices.
Collapse
Affiliation(s)
- P Dron
- Allergy Vigilance Network, Department of Internal Medicine, Clinical Immunology and Allergology University Hospital 29 av. du Maréchal de Lattre de Tassigny, 54035 Nancy
| | | | | | | | | | | | | | | | | | | |
Collapse
|